Nachrichten zur Neurocrine Biosciences Inc. Aktie

Neurocrine shares fall after mid-stage schizophrenia study results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences: Luvadaxistat Fails To Meet Primary Endpoint In Phase II INTERACT Study

TOKYO (dpa-AFX) - Neurocrine Biosciences (NBIX) said the investigational drug luvadaxistat did not meet primary endpoint in the phase II…

Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference

SAN DIEGO , Feb. 23, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will…

Neurocrine Biosciences Upping Marketing Spend To Support Its Platform

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

NEUROCRINE BIOSCIENCES INC: 10-K Report

10-K...…

More info. on Neurocrine Biosciences Q4 earnings

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Inc (NBIX) Q4 2020 Earnings Call Transcript

NBIX earnings call for the period ending December 31, 2020....…

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences, Inc. 2020 Q4 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences (NBIX) Q4 Earnings Top Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of 506.78% and -4.81%, respectively, for the quarter ended December 2020. Do the…

Neurocrine Biosciences Inc Q4 adjusted earnings Beat Estimates

WASHINGTON (dpa-AFX) - Neurocrine Biosciences Inc (NBIX) reported a profit for its fourth quarter that increased from the same period…

NEUROCRINE BIOSCIENCES INC: 8-K Report

8-K...…

Neurocrine Biosciences EPS beats by $0.01, misses on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results

SAN DIEGO , Feb. 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today…

Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program

CAMBRIDGE, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that Neurocrine Biosciences,…

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results

SAN DIEGO , Jan. 20, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced…

Neurocrine, Ionis, Vertex: Underperforming Healthcare Stocks Poised To Recover

Our theme of Out Of Favor Health Care Stocks includes health care stocks that have witnessed strong Revenue growth and…

Neurocrine Bio sees Ingrezza sales of $993M in FY20

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

SAN DIEGO , Jan. 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided…

Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

Um den gesamten Artikel unter barchart.com zu lesen, klicken Sie bitte auf die Überschrift...…

Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program

CAMBRIDGE, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that the U.S.…

Neurocrine Stock Looks Attractive In the Wake Of A 30% Correction

Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, has more room for…

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO , Nov. 19, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced…

Neurocrine Biosciences Hit By Multiple Setbacks

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences (NBIX) Reports Q3 Loss, Lags Revenue Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of -663.64% and -8.31%, respectively, for the quarter ended September 2020. Do the…

Neurocrine Biosciences Reports Third Quarter 2020 Financial Results

SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced…

Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

SAN DIEGO , Nov. 9, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today…

Neurocrine Biosciences Q3 2020 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Vertex, Neurocrine: Are These Out Of Favor Healthcare Stocks A Buy As Vaccine Nears?

Our indicative theme of Out Of Favor Healthcare Stocks Poised For Gains is down by about -13% year-to-date, compared to…

ACADIA, Neurocrine, Alkermes Are Out Of Favor. Is It Time To Buy?

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which…

Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy

U.S. Food and Drug Administration (FDA) Requests Additional Non-Clinical Data to Support Dose Justification Before Initiation of a Phase II…

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2020 Financial Results

SAN DIEGO , Oct. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today…

Neurocrine Presents Data, And Other News: The Good, Bad And Ugly Of Biopharma

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Looks Like A Long-Term Value After Share Price Decline

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

SAN DIEGO , Sept. 8, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present…

Neurocrine Bio to discuss data from movement disorder programs at scientific meetings between Sept. 10 - 16

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Neurocrine Biosciences to Present at the Citi 15th Annual BioPharma Virtual Conference

SAN DIEGO , Sept. 2, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Citi 15 …

Neurocrine Biosciences Inc (NBIX) Q2 2020 Earnings Call Transcript

NBIX earnings call for the period ending June 30, 2020....…

Neurocrine Biosciences, Inc. 2020 Q2 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Top Analyst Upgrades and Downgrades: Charter, Clorox, FirstEnergy, Neurocrine, RingCentral, Roku, Seagate, Take-Two, Zillow and More

Um den gesamten Artikel unter feedproxy.google.com zu lesen, klicken Sie bitte auf die Überschrift...…